- Home
- TLN vs WAT Comparison
TLN vs WAT Comparison
Compare TLN & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLN
- WAT
- Stock Information
- Founded
- TLN 2015
- WAT 1958
- Country
- TLN United States
- WAT United States
- Employees
- TLN N/A
- WAT N/A
- Industry
- TLN Electric Utilities: Central
- WAT Biotechnology: Laboratory Analytical Instruments
- Sector
- TLN Utilities
- WAT Industrials
- Exchange
- TLN Nasdaq
- WAT Nasdaq
- Market Cap
- TLN 18.6B
- WAT 17.4B
- IPO Year
- TLN N/A
- WAT 1995
- Fundamental
- Price
- TLN $380.97
- WAT $373.32
- Analyst Decision
- TLN Strong Buy
- WAT Buy
- Analyst Count
- TLN 13
- WAT 13
- Target Price
- TLN $415.38
- WAT $379.00
- AVG Volume (30 Days)
- TLN 925.9K
- WAT 716.2K
- Earning Date
- TLN 11-05-2025
- WAT 11-04-2025
- Dividend Yield
- TLN N/A
- WAT N/A
- EPS Growth
- TLN N/A
- WAT 3.82
- EPS
- TLN 4.55
- WAT 10.88
- Revenue
- TLN $2,257,000,000.00
- WAT $3,105,638,000.00
- Revenue This Year
- TLN $13.60
- WAT $7.12
- Revenue Next Year
- TLN $72.74
- WAT $6.22
- P/E Ratio
- TLN $84.75
- WAT $34.13
- Revenue Growth
- TLN 11.95
- WAT 6.90
- 52 Week Low
- TLN $158.08
- WAT $275.05
- 52 Week High
- TLN $451.28
- WAT $423.56
- Technical
- Relative Strength Index (RSI)
- TLN 41.97
- WAT 73.04
- Support Level
- TLN $390.04
- WAT $340.09
- Resistance Level
- TLN $410.91
- WAT $382.02
- Average True Range (ATR)
- TLN 19.89
- WAT 11.56
- MACD
- TLN -1.69
- WAT 1.40
- Stochastic Oscillator
- TLN 42.92
- WAT 81.72
About TLN Talen Energy Corporation Common Stock
Talen Energy Corp is an independent power producer and energy infrastructure company. The company owns and operates approximately 10.7 gigawatts of power infrastructure in the United States. The group produces and sells electricity, capacity, and ancillary services into wholesale U.S. power markets, including PJM and WECC, with its generation fleet located in the Mid-Atlantic and Montana.
About WAT Waters Corporation
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions. In early 2026, Waters plans to merge with BD's life science and diagnostics business, which will substantially change those concentrations. Waters will wind up with more concentration in diagnostics (versus none now) and discovery-related life science tools.